Frontier Capital Management CO LLC Arvinas, Inc. Transaction History

Frontier Capital Management CO LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$32.47 - $57.24 $600,500 - $1.06 Million	-18,494 Reduced 71.23%	7,469 $255,000
Q3 2022 Nov 14, 2022	SELL	$41.87 - $57.99 $1.09 Million - $1.51 Million	-26,028 Reduced 50.06%	25,963 $1.16 Million
Q2 2022 Jul 20, 2022	BUY	$36.01 - $74.24 $1.04 Million - $2.14 Million	28,827 Added 124.45%	51,991 $2.19 Million
Q1 2022 Apr 14, 2022	SELL	$60.27 - $81.57 $3.77 Million - $5.1 Million	-62,560 Reduced 72.98%	23,164 $1.56 Million
Q4 2021 Jan 19, 2022	SELL	$65.85 - $96.21 $3.01 Million - $4.39 Million	-45,637 Reduced 34.74%	85,724 $7.04 Million
Q3 2021 Oct 19, 2021	BUY	$73.2 - $107.87 $9.62 Million - $14.2 Million	131,361 New	131,361 $10.8 Million

224

70.9M

1.52M

346K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $986M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Frontier Capital Management CO LLC, based on Form 13F filings with the SEC.

Stay updated on Frontier Capital Management CO LLC with notifications on news.